Barcelona, Spain, May 13th 2024. D-Sight, a pioneering spin-off company of Vall d’Hebron Research Institute (VHIR) dedicated to the discovery and development of new innovative therapeutic approaches for the treatment of neurodegenerative diseases of the retina; is thrilled to announce its strategic partnership with Famar Group, a European contract manufacturing and development organization serving the pharmaceutical industry. This collaboration will accelerate the development and production of clinical batches for D-Sight's eye drops solution intended for the treatment of early stages of diabetic retinopathy.